Compare TUYA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | TBPH |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 908.9M |
| IPO Year | 2021 | 2013 |
| Metric | TUYA | TBPH |
|---|---|---|
| Price | $1.87 | $17.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.49 | ★ $18.40 |
| AVG Volume (30 Days) | ★ 544.3K | 402.8K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $13.76 | $8.46 |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.61 | $13.08 |
| 52 Week High | $2.73 | $21.03 |
| Indicator | TUYA | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.12 | 63.76 |
| Support Level | $1.72 | $16.80 |
| Resistance Level | $2.00 | $17.17 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.08 | 82.05 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.